United States Drug Manufacturers - General news

10:11 17 Jul 2026

Ad Hoc News Balance sheet Main company 🇺🇸 United States

Grifols stock trades around recent lows as leverage and governance remain under scrutiny

Grifols stock is currently trading near multi-year lows due to persistent investor concerns regarding its high leverage and corporate governance issues. Despite recent quarterly revenue growth and efforts to improve efficiency, the company's significant debt load of over EUR 9 billion and past reporting …

GRFS main company

Sharemaestro market context Price below Trend Line 52 weeks -23.4%

08:38 17 Jul 2026

Simply Wall Street Earnings Main company 🇺🇸 United States

Pfizer (PFE) Could Be 16% Undervalued On New FDA Approval In Bladder Cancer

Pfizer (PFE) recently received FDA approval for PADCEV plus Keytruda for muscle-invasive bladder cancer, which could suggest a 16% undervaluation based on a fair value of $29.19 per share. Despite past share price pressure, the new oncology approval and strong late-stage pipeline in oncology …

PFE main company

Sharemaestro market context Price above Trend Line 52 weeks +8.9%

08:31 17 Jul 2026

MarketBeat Earnings Main company 🇺🇸 United States

Assetmark Inc. Purchases 15,719 Shares of Amgen Inc. $AMGN

Assetmark Inc. increased its stake in Amgen Inc. by 6.9% in the first quarter, purchasing an additional 15,719 shares to bring its total holdings to 243,853 shares valued at approximately $85.8 million. Amgen's stock currently holds an overall "Hold" consensus among analysts, with an …

AMGN main company

Sharemaestro market context Trend signal active 52 weeks +44.4%

08:11 17 Jul 2026

Novartis Deals and strategy Main company 🇺🇸 United States

Novartis marks 30 years of breakthroughs, building on 250 years of discovery to reimagine what medicine can do next

Novartis is celebrating its 30th anniversary, reflecting on a 250-year legacy of scientific discovery rooted in the merger of Ciba-Geigy and Sandoz. The company has pioneered significant medical advancements, including targeted cancer therapies, cell therapy, and gene therapy, continually pushing the boundaries of what …

NVS main company

Sharemaestro market context Trend signal active 52 weeks +22.5% · Next-week setup positive 61.2%

02:38 17 Jul 2026

TradingView Market update Main company 🇺🇸 United States

ETFs Investing in Pfizer Inc. Stocks

This article lists numerous Exchange Traded Funds (ETFs) that hold Pfizer Inc. (PFE) stocks. It provides a detailed table including each ETF's market value, weight of PFE in the fund, issuer, management style, focus, expense ratio, AUM, price, change, relative volume, and 3-year NAV …

PFE main company

Sharemaestro market context Price above Trend Line 52 weeks +8.9%

01:11 17 Jul 2026

더밀크 Market update Main company 🇺🇸 United States

Sanofi Doesn’t Want AI to Automate Work. It Wants to Reinvent It.

Sanofi is aiming to become the first biopharma company powered by AI at scale, applying AI throughout the entire medicine development journey from discovery to commercialization. Emmanuel Frenehard, Sanofi's Chief Digital Officer, emphasizes that AI should be used to reinvent business processes rather than …

SNY main company

Sharemaestro market context Price below Trend Line 52 weeks -10.1% · Next-week setup positive 56.1%

00:38 17 Jul 2026

매일경제 Deals and strategy Main company 🇺🇸 United States

U.S. pharmaceutical company Eli Lilly announced on the 16th that it has decided to acquire mental he..

Eli Lilly announced its decision to acquire Ataybekli, a mental health treatment developer, for up to $3.8 billion. Ataybekli specializes in psychedelic drug-based treatments for depression and counts billionaire investor Peter Thiel among its early investors. The final acquisition is contingent on the performance …

LLY main company

Sharemaestro market context Trend signal active 52 weeks +66.6% · Next-week setup positive 58.3%

00:10 17 Jul 2026

GlobeNewswire Regulatory and legal Main company 🇺🇸 United States

Novartis Fabhalta® (iptacopan) receives FDA traditional approval as first and only complement inhibitor to significantly slow kidney function decline in primary IgAN

Novartis announced that the FDA has granted traditional approval for Fabhalta (iptacopan) to slow kidney function decline in adults with primary IgA nephropathy (IgAN) at risk of disease progression. This approval, following an earlier accelerated approval, is based on data showing Fabhalta significantly slowed …

NVS main company

Sharemaestro market context Trend signal active 52 weeks +22.5% · Next-week setup positive 61.2%

23:52 16 Jul 2026

Simply Wall Street Earnings Main company 🇺🇸 United States

Is Gilead Sciences (GILD) Fully Valued Following Mixed Earnings And A Full Year EPS Miss?

Gilead Sciences (GILD) reported mixed Q2 earnings with revenue up 4.4% to $6.96 billion but missed full-year EPS estimates. While one valuation narrative suggests Gilead is 6.2% overvalued at $136.30 with a fair value of $128.38, another Discounted Cash Flow (DCF) model indicates it …

GILD main company

Sharemaestro market context Price above Trend Line 52 weeks +23.7%

23:11 16 Jul 2026

BioSpace Deals and strategy Main company 🇺🇸 United States

Organon to Report Second Quarter 2026 Results in Its Regularly Scheduled Form 10-Q Filing

Organon (NYSE: OGN) announced it will release its second-quarter 2026 financial results through its Form 10-Q filing with the SEC, along with a Form 8-K disclosing non-GAAP financial measures. Due to its pending acquisition by Sun Pharmaceutical Industries Limited, the company has suspended quarterly …

OGN main company

Sharemaestro market context Trend signal active 52 weeks +46.5%

23:07 16 Jul 2026

Stock Titan Market update Main company 🇺🇸 United States

Gilead Sciences (GILD) CFO sells 3,000 shares in pre-set 10b5-1 plan

Gilead Sciences' Chief Financial Officer, Andrew D. Dickinson, sold 3,000 shares of common stock on July 15, 2026, for approximately $390,000, under a pre-arranged Rule 10b5-1 trading plan. After this transaction, Dickinson still directly holds 168,646 shares. The sale was executed at an average …

GILD main company

Sharemaestro market context Price above Trend Line 52 weeks +23.7%

22:43 16 Jul 2026

Reuters Macro sensitivity Main company 🇺🇸 United States

EXCLUSIVE: Pfizer suspends sales of Premarin vaginal cream in India, citing supply challenges

Pfizer has temporarily suspended sales of Premarin vaginal cream in India due to supply challenges, significantly impacting the estrogen therapy options for millions of women experiencing menopause-related symptoms in the country. This suspension affects over half of the market for this type of medication …

PFE main company

Sharemaestro market context Price above Trend Line 52 weeks +8.9%

22:35 16 Jul 2026

GuruFocus Earnings Main company 🇺🇸 United States

Gilead Sciences Inc (GILD) Stock Up 3.5% but GF Value Says Overvalued -- GF Score: 69/100

Gilead Sciences Inc (GILD) saw its stock price rise by 3.5% on July 16, 2026, reaching $136.30. Despite this gain, GuruFocus's GF Value™ estimates the stock to be significantly overvalued at $96.17, implying a 41.7% premium. The GF Score™ of 69/100 suggests above-average performance …

GILD main company

Sharemaestro market context Price above Trend Line 52 weeks +23.7%

22:32 16 Jul 2026

Ad Hoc News Earnings Main company 🇺🇸 United States

Merck stock holds gains as Keytruda drives double digit revenue growth

Merck's stock reflects the company's strong performance, driven primarily by the oncology leader Keytruda, which has fueled double-digit revenue growth. In its latest quarter, total revenue reached $15 billion, with Keytruda sales alone hitting $6 billion, representing a 20% year-on-year increase. The company's vaccine …

MRK main company

Sharemaestro market context Trend signal active 52 weeks +60.7%

22:07 16 Jul 2026

Stock Titan Market update Main company 🇺🇸 United States

Gilead Sciences (NASDAQ: GILD) exec trades 3,000 shares under 10b5-1 plan

Johanna Mercier, Chief Comm & Corp Aff Officer of Gilead Sciences (NASDAQ: GILD), reported an open-market sale of 3,000 shares of common stock on July 15, 2026, at an average price of $129.9192 per share. This sale was conducted under a Rule 10b5-1 trading …

GILD main company

Sharemaestro market context Price above Trend Line 52 weeks +23.7%

22:02 16 Jul 2026

Investing.com Canada Earnings Main company 🇺🇸 United States

Gilead Sciences chief comm & corp aff officer sells $389,757 in stock

Johanna Mercier, Chief Communications & Corporate Affairs Officer at Gilead Sciences (NASDAQ:GILD), sold 3,000 shares of company stock for approximately $389,757 on July 15, 2026, as part of a pre-arranged trading plan. Despite the sale, the stock is considered potentially undervalued according to InvestingPro …

GILD main company

Sharemaestro market context Price above Trend Line 52 weeks +23.7%

21:44 16 Jul 2026

Zacks Earnings Main company 🇺🇸 United States

Will Amgen (AMGN) Beat Estimates Again in Its Next Earnings Report?

Amgen (AMGN) is analyzed for its potential to surpass earnings estimates in its upcoming report, leveraging its strong historical performance and positive Zacks Earnings ESP. The company has consistently beaten estimates in the last two quarters, and its current Earnings ESP of +1.17% combined …

AMGN main company

Sharemaestro market context Trend signal active 52 weeks +44.4%

21:40 16 Jul 2026

CryptoSlate Market update Main company 🇺🇸 United States

AstraZeneca Tokenized Stock price today, AZNX to USD chart, marketcap and volume

This article provides details on AstraZeneca Tokenized Stock (AZNX), a digital asset tracking AstraZeneca PLC's share price. It covers current price, market cap, trading volume, and market performance statistics. The article also explains AZNX's function as a tracker certificate within the xStocks ecosystem, offering …

AZN main company

Sharemaestro market context Price below Trend Line 52 weeks -1.4%

20:00 16 Jul 2026

The Globe and Mail Analyst action Main company 🇺🇸 United States

Analysts Are Bullish on Top Healthcare Stocks: Fractyl Health, Inc. (GUTS), AbbVie (ABBV)

Healthcare sector analysts have issued bullish sentiments on Fractyl Health, Inc. (GUTS) and AbbVie (ABBV). H.C. Wainwright analyst Joseph Pantginis maintained a Buy rating for Fractyl Health with an $8.00 price target, while William Blair analyst Matt Phipps maintained a Buy rating for AbbVie. …

ABBV main company

Sharemaestro market context Trend signal active 52 weeks +21.3% · Next-week setup positive 57.6%

19:47 16 Jul 2026

Investing.com Deals and strategy Main company 🇺🇸 United States

Freedom Capital upgrades Johnson & Johnson stock rating on strong quarter

Freedom Capital upgraded Johnson & Johnson (NYSE:JNJ) to Buy from Hold and raised its price target to $280 due to strong quarterly performance, particularly in TREMFYA, CAPLYTA, and SPRAVATO revenues. The firm is now more confident J&J will surpass its $100 billion revenue target …

JNJ main company

Sharemaestro market context Trend signal active 52 weeks +48.8%

19:41 16 Jul 2026

Benzinga Earnings Main company 🇺🇸 United States

FDA Approval Adds New Cholesterol Treatment Option in Merck Portfolio

Merck & Co. (NYSE: MRK) has received FDA approval for LIPFENDRA (enlicitide), a new oral PCSK9 inhibitor for adults with hypercholesterolemia, including heterozygous familial hypercholesterolemia (HeFH). This once-daily pill significantly reduced LDL-C in Phase 3 trials, with some studies showing up to a 60% …

MRK main company

Sharemaestro market context Trend signal active 52 weeks +60.7%

19:09 16 Jul 2026

Simply Wall Street Deals and strategy Main company 🇺🇸 United States

Johnson & Johnson (JNJ) Crosses $100 Billion As DePuy Synthes Buys Spine Tech

Johnson & Johnson (JNJ) has reached an annual revenue of over $100 billion for the first time, supported by strong Q2 results and raised guidance for 2026. This milestone is coupled with MedTech unit DePuy Synthes acquiring Expanding Innovations to bolster JNJ's presence in …

JNJ main company

Sharemaestro market context Trend signal active 52 weeks +48.8%

18:46 16 Jul 2026

Ad Hoc News Earnings Main company 🇺🇸 United States

AbbVie stock trades steadily as investors weigh Humira erosion and pipeline progress

AbbVie Inc. is navigating a transitional period marked by the decline of its flagship drug Humira due to biosimilar competition, balanced by the growth of its newer immunology and neuroscience treatments. Investors are focusing on the pace at which these new therapies can offset …

ABBV main company

Sharemaestro market context Trend signal active 52 weeks +21.3% · Next-week setup positive 57.6%

18:10 16 Jul 2026

Pharmaceutical Technology Earnings Main company 🇺🇸 United States

Novo secures European approval for oral Wegovy to extend lead over Lilly

Novo Nordisk has received European approval for its oral weight-loss drug, Wegovy (semaglutide), strengthening its lead over competitors like Eli Lilly in the obesity treatment market. This approval follows similar decisions in the US and UK, making oral Wegovy the first and currently only …

NVO main company

Sharemaestro market context Trend signal started 52 weeks -16.7%

18:07 16 Jul 2026

TradingView Earnings Main company 🇺🇸 United States

Will AbbVie's Neuroscience Franchise Deliver Another Strong Quarter?

AbbVie (ABBV) is set to report its second-quarter 2026 results, with investor attention on its neuroscience portfolio following a 26% revenue increase in Q1. The Zacks Consensus Estimate predicts 15% year-over-year growth for neuroscience revenues, driven by drugs like Botox Therapeutic, Vraylar, Ubrelvy, Qulipta, …

ABBV main company

Sharemaestro market context Trend signal active 52 weeks +21.3% · Next-week setup positive 57.6%

17:42 16 Jul 2026

marketscreener.com Analyst action Main company 🇺🇸 United States

Illumina, Inc., Formation Bio, Astrazeneca, Merck, and Eli Lilly and Company Expand Billion Cell Atlas Alliance with New Ai Drug Developers

Illumina has announced that its Billion Cell Atlas alliance has expanded to include new members, such as Formation Bio, bringing in more AI-driven drug developers. This alliance, which also includes AstraZeneca, Merck, and Eli Lilly and Company, uses Illumina's extensive genome-wide perturbation data to …

LLY main company MRK main company

Sharemaestro market context Trend signal active 52 weeks +66.6% · Next-week setup positive 58.3%

17:36 16 Jul 2026

MarketWatch Earnings Main company 🇺🇸 United States

Bristol Myers Squibb Co. stock outperforms competitors on strong trading day

Bristol Myers Squibb Co. (BMY) stock advanced 3.05% to $60.51 on Thursday, outperforming the broader market which saw the S&P 500 Index fall 0.51% and the Dow Jones Industrial Average fall 0.20%. This marks the stock's second consecutive day of gains despite an overall …

BMY main company

Sharemaestro market context Trend signal active 52 weeks +38.1%

17:07 16 Jul 2026

GuruFocus Market update Main company 🇺🇸 United States

Amgen Inc (AMGN) Stock Up 3.7% but GF Value Says Overvalued -- G

Amgen Inc's stock rose 3.7% to $371.58, but GuruFocus's GF Value™ indicates it is 5.1% overvalued compared to its fair value of $353.68. Despite a strong GF Score™ of 81/100, driven by high profitability and growth, the company shows weaknesses in financial strength and …

AMGN main company

Sharemaestro market context Trend signal active 52 weeks +44.4%

16:41 16 Jul 2026

Stock Titan Market update Main company 🇺🇸 United States

Amarin (AMRN) COO Keenan details RSU vesting and ADS tax withholding

David Paul Keenan, EVP and Chief Operating Officer of Amarin Corporation (AMRN), reported recent equity compensation activities. This included the vesting of 3,688 Restricted Stock Units (RSUs) linked to American Depositary Shares (ADSs) and the withholding of 1,926 ADSs to cover tax obligations. Following …

AMRN main company

Sharemaestro market context Price below Trend Line 52 weeks -12.0%

16:36 16 Jul 2026

Quiver Quantitative Earnings Main company 🇺🇸 United States

Why AbbVie (ABBV) Stock Is Up Today

AbbVie (ABBV) stock rose 3.3% today, driven by positive Wall Street sentiment and anticipation of its second-quarter earnings report. Analyst price target increases and new regulatory submissions for drugs like RINVOQ and SKYRIZI indicate strong pipeline momentum, despite ongoing challenges with Humira. Investors are …

ABBV main company

Sharemaestro market context Trend signal active 52 weeks +21.3% · Next-week setup positive 57.6%

16:35 16 Jul 2026

Bloomberg Law News Regulatory and legal Main company 🇺🇸 United States

Biogen Taps Biopharmaceutical Veteran as Chief Legal Officer

Biogen Inc. has appointed Michael J. Parini as its new chief legal officer, effective August 3rd, where he will oversee the company's global legal and compliance functions and report to the CEO. Parini brings over two decades of experience in the biopharmaceutical industry, having …

BIIB main company

Sharemaestro market context Trend signal active 52 weeks +50.6% · Next-week setup positive 55.3%

16:15 16 Jul 2026

TradingKey Earnings Main company 🇺🇸 United States

Merck & Co Inc Stock (MRK) Moved Up by 3.24% on Jul 16: Drivers Behind the Movement

Merck & Co Inc (MRK) stock rose by 3.24% on July 16, driven by optimism regarding its late-stage oncology pipeline, strategic advancements in its immunology portfolio, and diversification efforts. Analysts have increased price targets, citing strong performance in its vaccine and animal health segments. …

MRK main company

Sharemaestro market context Trend signal active 52 weeks +60.7%

16:15 16 Jul 2026

TradingKey Earnings Main company 🇺🇸 United States

AbbVie Inc Stock (ABBV) Moved Up by 3.32% on Jul 16: What Signal Does It Send?

AbbVie Inc.'s stock (ABBV) rose by 3.32% due to positive clinical trial outcomes for Skyrizi and Rinvoq, reinforcing its post-Humira growth strategy. Institutional investors are favoring healthcare stocks like AbbVie for its dividend profile and resilient cash flow, amidst a broader market shift from …

ABBV main company

Sharemaestro market context Trend signal active 52 weeks +21.3% · Next-week setup positive 57.6%

16:11 16 Jul 2026

Stock Titan Earnings Main company 🇺🇸 United States

GSK plc (NYSE: GSK) insiders add ADSs through dividend reinvestment

GSK plc reported that several senior leaders and non-executive directors acquired American Depositary Shares (ADS) between July 10 and July 14, 2026. These acquisitions were a result of the automatic reinvestment of cash dividends paid to shareholders on July 9, 2026, with ADS prices …

GSK main company

Sharemaestro market context Price below Trend Line 52 weeks +26.3% · Next-week setup positive 55.6%

15:44 16 Jul 2026

Market source Earnings Main company 🇺🇸 United States

Pfizer Stock Below 50-Day and 200-Day SMA: Buy the Dip or Exit Now?

Pfizer's stock is trading below its 50-day and 200-day simple moving averages, indicating investor caution due to declining COVID-related revenues and upcoming patent expirations. Despite these challenges and a dull 2026 financial outlook, the company is rebuilding its pipeline in oncology and obesity through …

PFE main company

Sharemaestro market context Price above Trend Line 52 weeks +8.9%

15:40 16 Jul 2026

Stock Titan Earnings Main company 🇺🇸 United States

Amarin (NASDAQ: AMRN) CLO gets RSU shares; some withheld for tax

Jonathan Provoost, EVP and Chief Legal Officer of Amarin Corporation, reported RSU activity where he acquired 3,688 American Depositary Shares (ADS) and had 1,264 ADS withheld for tax obligations, which is not considered a market sale. This activity relates to a 7,376-unit RSU grant …

AMRN main company

Sharemaestro market context Price below Trend Line 52 weeks -12.0%